Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (3291)	4/2/2001 12:19:45 PM
From: Marty	Read Replies (1) \| Respond to of 52153

"...anyone got a list of biotechs under $250m cap with less than three quarters of burn left (and with a respectable pipeline or technology) ? " Yep! NEOT Pfizer did a drug finder deal with their genomics subsidiary last month. They are starting a pivotal trial on their lead drug, Neotrofin, for nerve regeneration for Alzheimers this month. Within the last two weeks they began separate trials for Parkinson's and Spinal Cord Injuries, to cover your pipeline and technology qualification. The market cap is less than $100 million (!)at the moment and their cash is probably less than 3 quarters at current burn rate as a consequence of a death spiral financing they just got through. I think they want to go it alone as far as they can though.